Cigna Group

Cigna Group (CI) — Investment Memo

🐂 The Bull Case (Warren's voice)

• Why the moat is durable: Employers are locked in. Re‑enrolling thousands of employees, renegotiating drug formularies, disrupting care – the switching cost is brutal. Cigna’s 10‑K shows customer retention is high: the pain of leaving exceeds any small premium advantage. This is not a commodity; it’s a sticky annuity.
• Exceptional economics – where the real money lives: The headline 2.2% net margin is misleading. Evernorth (PBM) earns higher‑margin fees on drug rebates and administration – that’s the cash machine. The insurance side (Cigna Healthcare) provides float: $275B of premiums come in before claims are paid. On that float, Cigna earns investment income and creates a buffer. ROE hit 14.3% in 2025 – not spectacular, but consistently above cost of capital when you account for leverage.
• Price range for Berkshire: If we take the DCF at face value – $392.72 per share – that’s fair for a steady compounder. But Berkshire needs a margin of safety. At $294 (25% discount), the risk/reward becomes interesting. At $196 (50% discount), it’s a no‑brainer – you get a sticky, recurring business with a moat that will survive GLP‑1 spikes because employers have to offer health benefits. The current price (~$390) is fair but not compelling. Wait for a panic.

🐻 The Bear Case (Charlie inverts)

• Scenario 1: The GLP‑1 cost tsunami. Obesity drugs are wildly expensive and utilization is accelerating. Cigna’s 2.2% margin is a hair‑trigger. Contracts lock premiums for a year – if claims spike, net income turns negative. This is not “a bad year.” It’s a permanent shift in medical cost trend. Cigna can’t pass through costs fast enough. The moat of inertia won’t save earnings – it’ll only delay the bloodbath.
• Scenario 2: Regulatory decapitation of the PBM. Evernorth generates high‑margin rebate revenue. The Federal Trade Commission and Congress are circling. If drug rebates are banned or transparently passed to plan sponsors, the PBM fee machine collapses. That would cut Cigna’s profit by 40–50%. This is structural, not cyclical. Timeline: 3–5 years.
• Scenario 3: The Medicare Advantage retreat is a warning. Cigna sold its MA business in 2025 – admitting they couldn’t compete. That’s a permanent loss of a growth avenue. The core employer market is mature. Without MA, organic growth slows to GDP‑level. The only way to grow is more acquisitions – and the Express Scripts track record shows they destroy value.

Most likely scenario: GLP‑1 cost explosion combined with PBM margin compression. Within 5 years, net margins fall below 1% and the business becomes a low‑return utility. The moat of switching costs keeps revenues intact but profits vanish.

💰 Valuation & Margin of Safety

• DCF provided: $103.5B total equity / $392.72 per share (5.5% FCF growth, 10% discount, 3% terminal). This assumes the razor‑thin margin holds and growth continues. That assumption is heroic.
• Our intrinsic value estimate: $280 per share – applying a 7% FCF growth (not 5.5% – margins are contracting) and a 12% discount rate (higher risk from GLP‑1 and regulatory). This is a conservative, survival‑based value.
• 25% margin of safety entry: $210 per share (if you want a cushion against the bear case).
• 50% margin of safety entry: $140 per share (Buffett’s ideal – price in a permanent impairment).
• Current price (~$390): Expensive by 39% vs. our intrinsic value. There is no margin of safety. The market is pricing optimism that the moat will overcome structural threats. We disagree.

Verdict: PASS

• At $390, you are paying for a 2.2% margin business with massive tail risks from GLP‑1 costs and PBM regulation – the moat of switching costs is real, but it protects revenue, not profits.
• The 50% margin of safety entry of $140 is unlikely to be reached absent a crisis, and even then, the business model is too fragile to hold for twenty years.
• Cigna’s capital allocation history (overpaying for Express Scripts, retreating from Medicare Advantage) and missing financial data disqualify it for Berkshire – we want businesses we understand and can trust; this one fails both tests.